Results
|
|
9081.
|
|
|
|
9082.
|
|
|
|
9083.
|
|
|
|
9084.
|
|
|
|
9085.
|
|
|
|
9086.
|
|
|
|
9087.
|
|
|
|
9088.
|
|
|
|
9089.
|
|
|
|
9090.
|
|
|
|
9091.
|
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. [electronic resource] by
- van Kampen, R J W
- Ramaekers, B L T
- Lobbezoo, D J A
- de Boer, M
- Dercksen, M W
- van den Berkmortel, F
- Smilde, T J
- van de Wouw, A J
- Peters, F P J
- van Riel, J M G
- Peters, N A J B
- Tjan-Heijnen, V C G
- Joore, M A
Producer: 20170821
In:
European journal of cancer (Oxford, England : 1990) vol. 79
Availability: No items available.
|
|
|
9092.
|
|
|
|
9093.
|
|
|
|
9094.
|
|
|
|
9095.
|
|
|
|
9096.
|
|
|
|
9097.
|
|
|
|
9098.
|
|
|
|
9099.
|
|
|
|
9100.
|
|